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Maternal serum screening  
in the West Bank 
 
Abstract  
 
Objectives The aim of this second phase of study was to 
detect or confirm any change in the screening results of Triple 
tests carried out on Palestinian women living in the West Bank 
during the period 2004-2010 if compared to that done 
between 2000-2003. 
Methods Data on 1354 pregnant Palestinian and non-
Palestinian  women  living in the West Bank (Filipino women) 
who were offered the Triple test during the period 2004-2010 
were analyzed statistically using the Statistical Package for 
Social Sciences (SPSS) version 17 
Results In this study, out of 1354 subjects, 1267 were eligible 
for the final analysis. The mean expected age at delivery ± SE 
(standard error) of the Palestinian women was 27.02±0.17 
years compared with 25.5 ±0.2 years in the first study. The 
AFP results of the Palestinian women tested using AFP MoM 
cutoff of 2.5 showed that 2.7% had high concentrations 
compared with only 1.3% in the first study. Filipino women 
showed the same result for AFP. Our study showed that 
women with high risk of Down’s syndrome were 5% compared 
with 2.8% in the first phase of study. 
Conclusion   Our study showed that within about six years 
there is increase in both the percentage of women with high 
AFP results and with those with high risk of Down’s syndrome 
which becomes similar to that obtained in the international 
community. This may be due to direct result of the increase in 
the mean age of women. 
 
Introduction 
 
Antenatal testing describes procedures performed during 
pregnancy to detect health problems in the growing fetus. 
These tests can provide a non-invasive screening for Down’s 
syndrome (trisomy 21) and other congenital anomalies such 
as spina bifida and anencephaly (neural tube defects – NTDs) 
through the assessment of maternal serum markers and 
ultrasonography .1, 2  
Down’s syndrome (trisomy 21) is the most common 
cause of severe learning disability in children with an 
incidence of 1 in 800 live births .3 The incidence of Down’s 
syndrome in some Arab countries exceeds 1.7 per 1000 
compared to incidences of 1.0-1.4 per 1000 for other Arab 
populations .4 As a result of this high incidence, screening 
and diagnostic tests should be offered.  In our community the 
importance of such tests has been recognized and the first 
local study on this subject was published in 2005. 5 
         Screening tests for Down’s syndrome are either done in 
the first or second trimester. 3, 6 First trimester test is usually 
ordered between 11-13 weeks of pregnancy. This  test 
measures the levels of two serum markers, free β-human 
chorionic gonadotropin (free β-hCG) and Pregnancy 
Associated Plasma Protein-A (PAPP-A) in addition to a 
special ultrasound scan that measures the nuchal 
translucency (NT) thickness, a space at the back of the baby’s 
neck .7 These tests cannot evaluate the fetus's risk of 
developing NTDs. First trimester screening is not common in 
the Palestinian community and efforts are exerted to 
encourage women to do it in the near future. The most 
common test done by Palestinian pregnant women is the 
Triple test. 5 
The Triple and Quadruple tests are used to screen in 
the second trimester of pregnancy between 14 weeks and 20 
weeks of pregnancy.  It is ordered to help evaluate the risk 
that a fetus has certain abnormalities, including Down’s 
syndrome and NTDs.7, 8 The Triple test measures the levels 
of three markers in the serum of the pregnant women: Alpha-
fetoprotein (α-FP), Human Chorionic Gonadotropin (hCG) and 
unconjugated Estriol (uE3). 9 When Inhibin A is added to 
these three biochemical markers, the  
 detection rate of the test increases by 10% to about 75% and 
is called the Quadruple test. 10 Increased or decreased levels 
of the three serum markers can suggest the type of 
abnormality present. 11  
         A number of important factors can influence the results 
of the Triple test. These include: maternal age, race, weight, 
number of fetuses and gestational age. 3, 12 Women who 
have a positive screening test result for Down’s syndrome are 
usually referred for genetic counseling and further testing. 
  In this article we describe the results of Triple tests 
carried out on Palestinian and non-Palestinian women who 
came to perform this test in different areas of the West Bank 
during the period 2004-2010. 
 
Subjects and materials 
 
Laboratory methods  
All tests were performed in Zer laboratories in Jerusalem 
utilizing standardized techniques for analysis. Both AFP and 
hCG were performed using immunoradiometric assay (IRMA). 
AFP kit was produced by Byk-Santgtec Diagnostica-Germany, 
while the hCG kit was produced by ICN-USA. For uE3 the 
radioimmunoassay (RIA) kit used was a product of DSL-USA. 
ALPHA, which is special software for risk calculation was 
utilized in this study and produced by Logical Medical 
Systems, UK. The cut-off point utilized in this analysis was 
1:380 at term risks.  
 
Variables used in the study 
The following variables were used: age at expected date of 
delivery, weight in kilograms, gestational age in weeks, in vitro 
fertilization (IVF) status, twins status, AFP levels in IU/mL and 
multiples of the normal gestation-specific median (MOM), 
hCG in IU/mL and MOM, uE3 in ng/mL and MOM.  The 
variables were used to calculated risk for age alone and for 
the Triple test. 
 
Statistical analysis 
All data were entered into Statistical Package for Social 
Sciences (SPSS) version 17. Data cleaning was conducted 
and outliers were excluded, those included 29 twins 
pregnancies, 5 IVF, 1 unknown origin, and 52 Africans. A total 
1267 cases were included in the final analysis.  Basic 
descriptive statistics including means, medians, modes, 
standard deviation, and standard error were calculated. 
Frequencies were also calculated for relevant variables. Cross 
tabulations and Chi square test were used to explore the 
relation between different variables. 
 
 
Results 
 
Characteristics of the subjects 
 A total 1267 cases were investigated of which 88.4 % (1120) 
were Palestinian Arabs residing in the West Bank, while 
11.6% (147) were non-Arabs (Filipinos). The mean expected 
age at delivery ± SE (standard error) of all subjects was 
27.54±0.17 years while it was 27.02±0.17 years for 
Palestinian women and 31.47 ±0.45 years for Filipino women.  
11.8% (150) of the participants were 35 years old or above. 
The mean weight for women at the time of testing was 65.79 ± 
0.34 kilograms. The range of gestational age when the test 
was performed was 15 to 21 weeks, with a mean of 17.12 
±0.02. 
An audit of Palestinian and non-Palestinian women having 
Triple tests - Mutaz Akkawi, Rula Ghandour, Abdullatif 
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Individual 
test results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion    
Palestinian pregnant women started showing 
interest in screening for Down’s syndrome in 
the late 1990s. This is the second study 
performed in the Palestinian community in the 
last decade. In the period between 2004-2010, 
a group of Palestinian pregnant women were 
screened for Down’s syndrome using the Triple 
test. 
Neural tube defects (NTDs) are birth defects of 
the brain or spinal cord. In Jordan where a 
large number of Palestinians present for 
medical care - the NTD incidence was 
estimated to be 1.1 per 1000 births. 13 
Screening for NTDs using maternal serum 
alpha-fetoprotein is used to identify women at 
increase risk of carrying of fetus with an 
NTD.14, 15 The most commonly used AFP 
MoM cutoff in the United States is 2.5 MoM, 
yielding initial screen-positive rate of 1% to 3%. 
3 In this study, the AFP results of the 
Palestinian women tested using AFP MoM cutoff of 2.5 showed that 2.7% had high concentrations.  
Filipino women showed the same result for AFP.  These two results were in agreement with the initial screen-positive rate 
given for pregnant women in the United States.  
The AFP results of this study were higher than those shown for Palestinian women in our first study published in 2005. 5 in 
which the proportion with high levels was 1.3% among a population of 943. 
The Triple test was projected to detect about 60% of the Down’s syndrome pregnancies by identifying 5% of all pregnant 
women as having a screen-positive test result, performance based on pregnancies being dated via LMP. 3 Our study showed that the 
total with high risk of Down’s syndrome was 5%. 
Comparing this result with that published in 2005, 5 where the proportion with high risk was 2.8%, there was a noticeable 
increase in this percentage. This may be due at least in part to difference in the mean expected age at delivery ± SE (standard error) 
which was 27.02±0.17 years compared with 25.5 ±0.2 years in the first study. This study showed also that for Filipino women the 
proportion with high risk of Down’s syndrome was 6.1%. This higher value could also be attributed to age factor where the mean 
expected age at delivery of the Filipinos women sample was 31.47±0.45 years.    
When comparing age groups (< 35 and ≥35) with risk, it was found that there was almost 7 folds increase in risk and it was 
statistically significant (P<0.00).  This association stayed strong after controlling for ethnic origin (7 folds for Palestinian women and 9 
folds for Filipinos).   
When comparing the risk percentages for Down’s syndrome of the total sample tested of both the Palestinian and Filipinos, there was 
no statistically significant difference in risk between them.  
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Age (years) 
Elevated  
AFP 
(%) 
Elevated 
hCG 
(%) 
Reduc
ed hCG 
(%) 
Reduc
ed uE3 
(%) 
Calculate
d Risk 
(%)* 
(age+ 
triple 
test) 
P-value 
(Risk) 
Arabs 
Age 
Group 
15-24 
n=448 2.5 3.6 0.9 0.2 2.2 
0.000 
25-34 
n=561 2.5 2.7 1.2 0.0 3.7 
>35 
n=111 4.5 2.7 0.0 0.0 22.5 
Total(N=1120) 2.7 3.0 1.0 0.0 5.0 
Filipino
s 
Age 
Group 
15-24 
n=17 0.0 0.0 0.0 0.0 0.0 
0.001 
25-34 
n=91 3.3 3.3 1.1 0.0 2.2 
>35 
n=39 2.6 5.1 0.0 0.0 17.9 
Total (N=147) 2.7 3.4 0.7 0.0 6.1 
Concentration 
(Mean ±  SE 
Arabs 
(Palestinians) 
N=1120 
Non Arabs 
(Filipinos) 
N=147 
AFP 40.88±0.59 52.01±1.97 
hCG 27.78±0.66 32.37±1.8 
uE3 1.27±0.07 1.50±0.05 
Characteristics 
Table 1: Mean serum concentrations of the 
three markers of the triple test. 
Marker  
Arabs 
(Palestinians) 
N=1120  
Median MoM 
(Interquartile 
Range) 
Mean log10 
MoM(SD) 
Median MoM 
(Interquartile 
Range) 
Mean log10 
MoM(SD) 
AFP 1.00  (0.76-1.29) 0.01 (0.22) 
1.16 
(0.91-1.48) 0.08 (0.20) 
hCG 0.99 (0.65-1.46) -0.01 (0.29) 
1.04 
(0.73-1.52) 0.02 (0.25) 
uE3 1.06 (0.84-1.31) 0.02 (0.16) 
1.28 
(1.01-1.60) 0.09 (0.16) 
Non Arabs 
(Filipinos) 
N=147  
Table 2: Median serum concentration (MoM) and  mean log10 for 
the 3 markers of the triple test * 
Table 3: Triple test results for 1267 women and calculated risk by age group 
and origin  
* SD= standard deviation  
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Crown-Rump Length and 
Gestational Age 
 
“The optimal gestational age for measurement of fetal 
NT is 11 weeks to 13 weeks 6 days.  The minimum fetal 
crown-rump length should be 45mm and the maximum 
84mm.” (Nicolaides KH, www.fetalmedicine.com/fmf//
FMF-English.pdf) 
 
Although not explicitly stated, this equivalency of crown 
rump length (CRL) and gestational age (GA) appears to 
be based on the formula of Robinson and Fleming (1975) 
because this appears to give the closest match among 
the most commonly used conversion formulae available 
(see Table).  But many MFM centers often do use the 
alternative conversions - including the newly 
recommended equation of Loughna et al (2009).  The 
Table illustrates that there are differences for the various 
available formulae and these differences are most 
apparent for higher CRL pregnancies.    The curve of 
Daya (1993) appears to be an outlier at higher CRL 
values but the other curves also vary by up to 4 days. 
(a)  Based on the “point estimate“ formula 
(b)  Based on a modified formula as described by Pedersen 
(1982) 
 
The use of alternative conversions from CRL to GA 
poses several problems.  First, it creates an ambiguity 
as to which patients are within an acceptable range for 
NT or serum test measurement.  Should we use 45-84 
mm or 11-13 weeks 6 days?  If the latter, which curve 
should we use?  Second, imprecise risk estimates can 
arise because the serum test normal median values 
(and sometimes NT medians) are based on GA rather 
than CRL.  A laboratory may construct its medians 
based on data from heterogeneous conversions of CRL 
to GA derived from multiple MFM practices.  It will then 
convert patients’ results into MoMs on the basis of that 
heterogeneous data.  But an individual woman’s GA was 
based on a single method for dating that may depart 
from the consensus. Therefore, the MoMs can be 
inaccurate.  Third, the statistical parameters in the risk 
calculation algorithm are also GA dependent reflecting 
the differences in efficacy of the screening at different 
times.  An individual risk calculation could therefore also 
be based on statistical parameters that are not optimal 
for that particular patient.  These difficulties will mostly 
affect cases that are screened close to the upper CRL/
GA limit. 
 
The problems could be minimized if normal median 
values and statistical parameters were routinely 
developed from a regression of the measurements 
against CRL rather than GA.  It would also be very 
helpful if the Fetal Medicine Foundation FMF) and the 
Nuchal Translucency Quality Review (NTQR) program 
would provide a single recommendation for CRL/GA 
conversion and redefine (or reiterate) the recommended 
range for NT measurement. 
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  ≥  45mm ≤ 84mm 
  ≥ weeks + days ≤ weeks + days 
Loughna et al, 2009 11 + 2 14 + 1 
Kuhn et al, 1995 11 +2 14 + 0 
Daya 1993 11 + 3 13 + 3 
Hadlock et al 1992 11 + 3 14 + 2 
Nelson 1981 11 + 1 14 + 3 
Drumm 1977 11 + 2 14 + 2 
Robinson and Fleming, 1975 (a) 11 + 1 13 + 6 
Robinson and Fleming, 1975 (b) 11 + 0 14 + 0 
